Capmatinib (Tabrecta), a selective inhibitor of the mesenchymal-epithelial transition (MET) receptor, showed significant antitumor activity in patients with metastatic non–small-cell lung cancer (NSCLC) and gene mutations that lead to MET exon 14 skipping, according to the results of a recently published study. Read More ›